[Advances in Hyperprogressive Disease in Patients with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
Hyperprogressive disease
Immune checkpoint inhibitors
Immunotherapy
Lung neoplasms
Journal
Zhongguo fei ai za zhi = Chinese journal of lung cancer
ISSN: 1999-6187
Titre abrégé: Zhongguo Fei Ai Za Zhi
Pays: China
ID NLM: 101126433
Informations de publication
Date de publication:
20 Apr 2021
20 Apr 2021
Historique:
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
6
10
2021
Statut:
ppublish
Résumé
Hyperprogressive disease (HPD) is a novel pattern of progression caused by immune checkpoint inhibitors (ICIs). It is characterized by a dramatic tumor surge and is associated with poor clinical outcomes. Up to now, the definition of HPD is still controversial across various studies. Although it has been indicated that HPD has related to multiple clinicopathological features and genetic alterations, it is lack of biomarker to predict its occurrence, and the potential mechanism remains unknown. This review is to summarize current data on HPD specialized in the field of non-small cell lung cancer. And we expect to provide helpful clinical strategies for oncologists using ICIs.
. 【中文题目：晚期非小细胞肺癌免疫治疗超进展的研究进展】 【中文摘要：超进展（hyperprogressive disease, HPD）是一种由免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）治疗导致的进展模式。它表现为肿瘤爆发式生长和极差的患者预后。目前各研究中HPD的定义不尽相同。虽然已经发现HPD与多种临床病理特点和基因类型有关，但目前仍没有可以准确预测它的肿瘤标志物，而且潜在的机制也尚在研究中。本文着眼于晚期非小细胞肺癌，对HPD的研究现状进行综述，以期给采用ICIs药物治疗患者的临床医生提供有益的参考 。
】 【中文关键词：肺肿瘤；超进展；免疫检查点抑制剂；免疫治疗】.
Autres résumés
Type: Publisher
(chi)
【中文题目：晚期非小细胞肺癌免疫治疗超进展的研究进展】 【中文摘要：超进展（hyperprogressive disease, HPD）是一种由免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）治疗导致的进展模式。它表现为肿瘤爆发式生长和极差的患者预后。目前各研究中HPD的定义不尽相同。虽然已经发现HPD与多种临床病理特点和基因类型有关，但目前仍没有可以准确预测它的肿瘤标志物，而且潜在的机制也尚在研究中。本文着眼于晚期非小细胞肺癌，对HPD的研究现状进行综述，以期给采用ICIs药物治疗患者的临床医生提供有益的参考 。
】 【中文关键词：肺肿瘤；超进展；免疫检查点抑制剂；免疫治疗】.
Identifiants
pubmed: 33910275
doi: 10.3779/j.issn.1009-3419.2021.101.08
pmc: PMC8105608
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
chi
Sous-ensembles de citation
IM
Pagination
271-278Références
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Br J Cancer. 2012 Feb 28;106(5):854-7
pubmed: 22281665
Future Oncol. 2019 Aug;15(23):2743-2757
pubmed: 31339060
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33051342
Eur J Immunol. 2021 Apr;51(4):956-964
pubmed: 33506525
Sci Rep. 2020 Feb 27;10(1):3565
pubmed: 32107407
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
BMC Cancer. 2021 Jan 5;21(1):19
pubmed: 33402127
J Thorac Oncol. 2017 Aug;12(8):1268-1279
pubmed: 28483607
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Clin Cancer Res. 2014 Jan 1;20(1):246-52
pubmed: 24240109
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Zhongguo Fei Ai Za Zhi. 2020 Feb 20;23(2):65-76
pubmed: 32093450
Clin Cancer Res. 2020 Apr 15;26(8):1846-1855
pubmed: 31757877
Nature. 2017 Dec 7;552(7683):121-125
pubmed: 29143824
Nat Genet. 2017 Nov;49(11):1567-1575
pubmed: 28991255
J Thorac Oncol. 2019 Sep;14(9):1608-1618
pubmed: 31195179
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
Oncotarget. 2016 Feb 16;7(7):7993-8005
pubmed: 26783960
Ann Oncol. 2019 Mar 1;30(3):385-396
pubmed: 30657859
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
Lung Cancer. 2021 Feb;152:109-118
pubmed: 33385736
Clin Exp Immunol. 2020 Dec;202(3):353-362
pubmed: 32757277
Immunotherapy. 2019 Aug;11(12):993-1003
pubmed: 31319742
Immune Netw. 2020 Dec 21;20(6):e48
pubmed: 33425433
Semin Oncol. 2017 Feb;44(1):3-7
pubmed: 28395760
J Nucl Med. 2020 Jun;61(6):821-826
pubmed: 31862803
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683809
J Thorac Oncol. 2018 Dec;13(12):1884-1896
pubmed: 30267840
ESMO Open. 2020;5(1):e000614
pubmed: 33551066
iScience. 2018 Nov 30;9:258-277
pubmed: 30439581
Lung Cancer. 2020 Jan;139:18-21
pubmed: 31704279
Lung Cancer. 2017 Oct;112:90-95
pubmed: 29191606
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
Cancers (Basel). 2020 Feb 04;12(2):
pubmed: 32033028